Skip to main content
Andrew E. Aplin on Muck Rack

Andrew E. Aplin

As seen in: Nature, Wiley Online Library, The Conversation, Cell Press, Times Higher Education, Healio, Cancer Discovery
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew E.

Contact Andrew E., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

S-phase targeted treatment triggers caspase-dependent lytic immunogenic cell death with pyroptotic features in cancers

|
By Rituparna Bhatt, Dan A. Erkes, Alexis Bonfim-Melo, Enaam Alghamdi, Sheena M. Daignault-Mill, Yoon Lim, Aditya Gopalakrishnan, Xin Yee Ong, Anastasia Gandini, Martina Proctor, Sharad Kumar, Zhen Zeng, Nikolas K. Haass, Mathew Jones, Paul Clarke Verified, Andrew E. Aplin, Brian Gabrielli, Koyo Kinase
| Nature Verified
Abstract Immunogenic cell death (ICD) is a type of cell death that can enhance anti-tumour immune responses of chemotherapies and targeted therapies by releasing DAMPs and cytokines that activate dendritic cells and T cells, thereby engaging the patient’s immune system to combat the cancer. Pyroptosis and necroptosis are strongly immunogenic because they release DAMPs and inflammatory signals through pore-forming proteins, whereas apoptosis can be tolerogenic.
Open in Who Shared Issue with article?

SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target - Cell Death & Disease

|
By Yann Cheli, Julien Cherfils-Vicini, Andrew E. Aplin, Valeria Naim
| Nature Verified
Abstract Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, we conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin regulators. We revealed that the lysine methyltransferase, SETDB1, plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 deficiency induces a DNA damage response, senescence-like state and growth arrest.
Open in Who Shared Issue with article?

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

|
By Simone Lubrano, Rodolfo Daniel Cervantes-Villagrana, Farhoud Faraji, Sydney I. Ramirez, Kuniaki Sato, Sendi R. Adame-Garcia, Adam Officer, Nadia Arang, Damiano C. Rigiracciolo, Claudia Martini, Yiyu Wang, Fleur M. Ferguson, Antonietta Bacchiocchi, Ruth Halaban, Sílvia Puigarnau Coma, Sheri Holmen, Jonathan A. Pachter, Andrew E. Aplin, J. Silvio Gutkind
| Cell Press Verified
Keywords avutometinib signal transduction targeted therapies FAK resistance BRAF MEK melanoma MAPK signaling immunotherapy Get full text access Log in, subscribe or purchase for full access. References 1. Siegel, R.L. ∙ Giaquinto, A.N. ∙ Jemal, A. Cancer statistics, 2024 CA Cancer J. Clin. 2024; 74:12-49 2. Davies, H. ∙ Bignell, G.R. ∙ Cox, C. ... Mutations of the BRAF gene in human cancer Nature. 2002; 417:949-954 3. Lavoie, H. ∙ Therrien, M. Regulation of RAF protein kinases in ERK signalling Nat. Rev. Mol.
Open in Who Shared Issue with article?
See all 22 licensed articles (23 Total)